Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

The findings, published in ACS Nano, show that just two doses of the experimental therapy achieved 97.5% tumor growth inhibition in a human AML xenograft mouse model — 59-fold more effective than standard 5-fluorouracil (5-FU) treatment, with no observable side effects.

For a disease with a grim 29% 5-year survival rate — and a cure rate of only 15% in patients older than 70 years — the findings offer a glimpse of how rethinking drug structure, not just chemistry, could advance cancer care.

Mirkin frames the findings within what he calls “the era of structural nanomedicine,” the idea that how you arrange medicinal components at the nanoscale matters as much as the molecules themselves.